We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RIGL market cap is 289.59M. The company's latest EPS is USD -1.4244 and P/E is -11.54.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 28.13M | 35.79M | 29.53M | 36.84M | 55.31M |
| Operating Income | -4.47M | 1.97M | -6.97M | 447k | 14.06M |
| Net Income | -5.69M | 737k | -8.25M | -1.03M | 12.42M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 59.29M | 108.62M | 149.24M | 120.24M | 116.88M |
| Operating Income | -69.09M | -28.97M | -12.5M | -55.55M | -20.49M |
| Net Income | -66.89M | -29.74M | -17.91M | -58.57M | -25.09M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 115.32M | 117.23M | 126.52M | 128.41M | 139.42M |
| Total Liabilities | 147.16M | 145.87M | 158.19M | 158.32M | 154.06M |
| Total Equity | -31.83M | -28.64M | -31.67M | -29.91M | -14.64M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 147.57M | 110.38M | 167.33M | 134.28M | 117.23M |
| Total Liabilities | 93.75M | 76.35M | 136.95M | 147.9M | 145.87M |
| Total Equity | 53.82M | 34.03M | 30.37M | -13.62M | -28.64M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 497k | -5.74M | -5.01M | -4.71M | 16.97M |
| Investing | 2.58M | -4.3M | 313k | 11.24M | 15.04M |
| Financing | 17.88M | 18.37M | -2.51M | -3.26M | -13.11M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -41.51M | -52.19M | 5.88M | -73.76M | -5.74M |
| Investing | -23.66M | 47.47M | -80.04M | 72.78M | -4.3M |
| Financing | 11.37M | 12.57M | 62.68M | 6.55M | 18.37M |
| Market Cap | 289.59M |
| Price to Earnings Ratio | -11.54 |
| Price to Sales Ratio | 2.48 |
| Price to Cash Ratio | 8.83 |
| Price to Book Ratio | -10.11 |
| Dividend Yield | - |
| Shares Outstanding | 17.62M |
| Average Volume (1 week) | 189.39k |
| Average Volume (1 Month) | 201.24k |
| 52 Week Change | 15.77% |
| 52 Week High | 29.82 |
| 52 Week Low | 7.4843 |
| Spread (Intraday) | 0.51 (3.11%) |
| Company Name | Rigel Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.rigel.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
